Safety-net burden linked with poorer inpatient cirrhosis outcomes
June 21, 2021
Even so, hospitalizations and mortality were still higher in Black patients than White patients after controlling for hospitals’ safety-net burden.
Updated USPSTF HBV screening recommendation may be a ‘lost opportunity’
January 12, 2021
The recommendation defines risk groups more narrowly than the CDC, AASLD, and some research suggests risk-based screening is ineffective for chronic conditions.
INR fails to predict bleeding in patients with cirrhosis
October 6, 2020
The investigators hope the study findings reinforce minimizing administration of fresh frozen plasma for inappropriate correction of international normalized ratio, which carries a multitude of adverse effects among cirrhotic patients.
Tools emerging to predict liver failure in cirrhosis
September 9, 2020
Systemic inflammation, with high levels of proteins, is one of the mechanisms that leads to organ failure.
New CDC guidance for health care personnel exposed to HCV
July 24, 2020
Baseline testing of the source patient and the HCP should be performed as soon as possible, preferably within 48 hours of exposure.
Hep C sofosbuvir/daclatasvir combo promising for COVID-19
July 13, 2020
“We need to remember that conducting research amidst a pandemic with overwhelmed hospitals is a clear challenge, and we cannot be sure of success.”
CDC: Screen nearly all adults, including pregnant women, for HCV
April 10, 2020
Screening should go beyond baby boomers.
See acute hepatitis? Consider COVID-19, N.Y. case suggests
April 9, 2020
This is the first documented instance of a patient with COVID-19 presenting with acute hepatitis as the primary symptom before developing respiratory symptoms.
Patients with COVID-19 may face risk for liver injury
March 19, 2020
Mechanisms of damage remain unclear, but could include virus-, immune-, or drug-induced injury.
What’s new in hepatitis C: Four themes that dominated at the Liver Meeting
November 22, 2019
BOSTON – AASLD highlights included treatment of persons who inject drugs, new directions in pangenotypic therapy, benefits of sustained virologic response, preemptive therapy in donor-positive organ transplant.